臨床泌尿器科77巻2号

2023年02月発行

特集 徹底解説!　過活動膀胱（OAB）の診療ストラテジー

〈難治性過活動膀胱に対する治療〉

難治性過活動膀胱に対するボツリヌス療法

著者： 舟橋康人¹

所属機関： ¹みちかぜクリニック

ページ範囲：P.188 - P.193

文献概要

▶ポイント

・薬物療法不応性の難治性過活動膀胱（rOAB）に対しても，ボツリヌス療法により切迫性尿失禁が約2割で消失し，約6割で半減する．

・効果持続期間は症例によりさまざまであり予測は難しいが，平均4〜9か月ほどである．

・副作用として排尿障害が懸念されるが，尿閉により間欠導尿を要する症例は約1〜6％ほどである．また導尿を要したとしても，切迫性尿失禁のある状態よりQOLは高い印象がある．

参考文献

1） 日本泌尿器科学会, 他 （編） : 過活動膀胱診療ガイドライン ［第3版］. リッチヒルメディカル, 東京, 2022

2） Kuo HC, et al : Intravesical Botulinum Toxin-A Injections Reduce Bladder Pain of Interstitial Cystitis/Bladder Pain Syndrome Refractory to Conventional Treatment ― A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Neurourol Urodyn 35 : 609-614, 2016

3） Khera M, et al : Botulinum Toxin A Inhibits ATP Release from Bladder Urothelium After Chronic Spinal Cord Injury. Neurochem Int 45 : 987-993, 2004

4） Chuang YC, et al : Intravesical Botulinum Toxin A Administration Produces Analgesia Against Acetic Acid Induced Bladder Pain Responses in Rats. J Urol 172 : 1529-1532, 2004

5） Giannantoni A, et al : Botulinum-A Toxin Injections into the Detrusor Muscle Decrease Nerve Growth Factor Bladder Tissue Levels in Patients with Neurogenic Detrusor Overactivity. J Urol 175 : 2341-2344, 2006

6） Apostolidis A, et al : Decreased Sensory Receptors P2X3 and TRPV1 in Suburothelial Nerve Fibers Following Intradetrusor Injections of Botulinum Toxin for Human Detrusor Overactivity. J Urol 174 : 977-982, 2005

7） Yokoyama O, et al : OnabotulinumtoxinA （Botulinum Toxin Type A） for the Treatment of Japanese Patients with Overactive Bladder and Urinary Incontinence : Results of Single-Dose Treatment from a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial （Interim Analysis）. Int J Urol 27 : 227-234, 2020

8） Nitti VW, et al : OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence : Results of a Phase 3, Randomized, Placebo Controlled Trial. J Urol 189 : 2186-2193, 2013

9） Chapple C, et al : OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence : A Randomised, Double-Blind, Placebo-Controlled Trial. Eur Urol 64 : 249-256, 2013

10） Hamid R, et al : OnabotulinumtoxinA Is a Well Tolerated and Effective Treatment for Refractory Overactive Bladder in Real-World Practice. Int Urogynecol J 32 : 65-74, 2021

11） McCammon K, et al : Early and Consistent Improvements in Urinary Symptoms and Quality of Life with OnabotulinumtoxinA in Patients with Overactive Bladder and Urinary Incontinence : Results from a Randomized, Placebo-controlled, Phase IV Clinical Trial. Female Pelvic Med Reconstr Surg 27 : 450-456, 2021

12） Sievert KD, et al : OnabotulinumtoxinA 100 U Provides Significant Improvements in Overactive Bladder Symptoms in Patients with Urinary Incontinence Regardless of the Number of Anticholinergic Therapies Used or Reason for Inadequate Management of Overactive Bladder. Int J Clin Pract 68 : 1246-1256, 2014

13） Nitti VW, et al : Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome : Final Results of a 3.5-Year Study. J Urol 196 : 791-800, 2016

14） Patel DN, et al : What Is the True Catheterization Rate After Intravesical OnabotulinumtoxinA Injection? Int Urogynecol J 29 : 1005-1009, 2018

15） Kennelly M, et al : Clean Intermittent Catheterization Rates After Initial And Subsequent Treatments with OnabotulinumtoxinA for Non-Neurogenic Overactive Bladder in Real-World Clinical Settings. Curr Med Res Opin 34 : 1771-1776, 2018

16） Abrar M, et al : Predictors of Poor Response and Adverse Events Following Botulinum Toxin A for Refractory Idiopathic Overactive Bladder : A Systematic Review. Eur Urol Focus 7 : 1448-1467, 2021

17） Šámal V, et al : Intravesical Loss of OnabotulinumtoxinA During Endoscopic Intradetrusor Injection ― A Multicenter Experience. Int Neurourol J 24 : 59-65, 2020

18） Mehnert U, et al : A Morphological Evaluation of Botulinum Neurotoxin A Injections into the Detrusor Muscle Using Magnetic Resonance Imaging. World J Urol 27 : 397-403, 2009

19） Purves JT, et al : A Three Dimensional Nerve Map of Human Bladder Trigone. Neurourol Urodyn 36 : 1015-1019, 2017

20） Jo JK, et al : The Effect of OnabotulinumtoxinA According to Site of Injection in Patients with Overactive Bladder : A Systematic Review and Meta-Analysis. World J Urol 36 : 305-317, 2018

21） Avallone MA, et al : Less Is More-A Pilot Study Evaluating One to Three Intradetrusor Sites for Injection of OnabotulinumtoxinA for Neurogenic and Idiopathic Detrusor Overactivity. Neurourol Urodyn 36 : 1104-1107, 2017

22） Ton J, et al : Outcomes of a Single Trigone-Only vs. 20 Trigone-Sparing Injections of OnabotulinumtoxinA for Refractory Overactive Bladder （OAB）. Int Urol Nephrol 53 : 1067-1072, 2021

23） Noblett K, et al : Results of a Prospective, Multicenter Study Evaluating Quality of Life, Safety, and Efficacy of Sacral Neuromodulation at Twelve Months in Subjects with Symptoms of Overactive Bladder. Neurourol Urodyn 35 : 246-251, 2016

24） Moon KH, et al : Prospective Trial of Sacral Neuromodulation for Refractory Overactive Bladder Syndrome in Korean Patients. Low Urin Tract Symptoms 6 : 175-179, 2014

25） Brazzelli M, et al : Efficacy and Safety of Sacral Nerve Stimulation for Urinary Urge Incontinence : A Systematic Review. J Urol 175 : 835-841, 2006

26） Amundsen CL, et al : Two-Year Outcomes of Sacral Neuromodulation versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence : A Randomized Trial. Eur Urol 74 : 66-73, 2018

27） Schwantes U, et al : Refractory Overactive Bladder : A Common Problem? Int Urogynecol J 26 : 1407-1414, 2015